Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2009. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility, specifically regarding the GlaxoSmithKline Executive Supplemental Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific equity transaction rather than general financial performance.
Material Changes
The filing details a late notification regarding changes in the interests of David Pulman in Ordinary share ADRs. The transaction involved the release of 2,363.38 Ordinary share ADRs under the Plan and the subsequent sale of 733.38 Ordinary share ADRs at a price of $35.26 per ADR on January 30, 2009, to meet tax liabilities. The delay in notification was attributed to an administrative error.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies beyond the administrative error noted regarding the timing of the director transaction notification.
Investor Verification Points
- Verify the total number of ADRs released (2,363.38) and sold (733.38) for David Pulman.
- Confirm the transaction date of January 30, 2009, and the sale price of $35.26 per ADR.
- Note the administrative error that caused the late notification of this transaction.